Formulary Watch |

All News - Page 10

Express Scripts Launches New Cost Plus Drug Model
Express Scripts Launches New Cost Plus Drug Model
Express Scripts Launches New Cost Plus Drug Model
November 15, 2023
This is the latest offering by Express Scripts that aims to bring transparency to prescription drug costs.
Bimzelx, the Newest Psoriasis Treatment, is Now Available
Bimzelx, the Newest Psoriasis Treatment, is Now Available
Bimzelx, the Newest Psoriasis Treatment, is Now Available
November 14, 2023
Bimzelx is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
Is Home-Based CAR-T Therapy Possible?
Is Home-Based CAR-T Therapy Possible?
Is Home-Based CAR-T Therapy Possible?
November 14, 2023
The results of a recent feasibility study on the outpatient administration of cell therapies is creating growing interest in whether home-based management may be possible in the future.
Cigna Makes Changes to Drugs Lists for 2024
Cigna Makes Changes to Drugs Lists for 2024
Cigna Makes Changes to Drugs Lists for 2024
November 10, 2023
Beginning Jan. 1, 2024, Cigna Healthcare’s formulary changes mostly impact generics and biosimilars.
Drug Spend for IBD Drugs Could Shift to Pharmacy Benefit
Drug Spend for IBD Drugs Could Shift to Pharmacy Benefit
Drug Spend for IBD Drugs Could Shift to Pharmacy Benefit
November 9, 2023
In her review of the specialty drug pipeline, Evernorth's Aimee Tharaldson said upcoming approvals for Crohn’s and colitis drugs could further shift the drug spend from the medical benefit to the pharmacy one.
Lilly’s Weight Loss Drug Approved by the FDA
Lilly’s Weight Loss Drug Approved by the FDA
Lilly’s Weight Loss Drug Approved by the FDA
November 8, 2023
Tirzepatide, with the brand name Zepbound, is expected to be available by the end of the year in six doses at a list price of $1,059.87, which is about 20% lower than semaglutide.
Postpartum Depression Therapy to Launch with $15,900 Price
Postpartum Depression Therapy to Launch with $15,900 Price
Postpartum Depression Therapy to Launch with $15,900 Price
November 8, 2023
Zurzuvae, the first oral therapy for postpartum depression, will launch in December.
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
November 7, 2023
Using an AI platform, Magellan Health was able to better support providers in prescribing behavioral health medications and addressing medication problems, which reduced pharmacy costs and increased adherence.
Optum Rx Announces Formulary Exclusions for 2024
Optum Rx Announces Formulary Exclusions for 2024
Optum Rx Announces Formulary Exclusions for 2024
November 6, 2023
First in class, biosimilars, oncology drugs and even some generics have been added to Optum Rx’s list of exclusions for 2024.
ICER: Greater Transparency of Coverage Policies Needed
ICER: Greater Transparency of Coverage Policies Needed
ICER: Greater Transparency of Coverage Policies Needed
November 3, 2023
The Institute for Clinical and Economic Review’s fair access report found that for the drugs assessed, formularies provided fair access, but it was difficult to determine how well that translates into real-world access and affordability for patients.
Payer Coverage of Biosimilars Varies by Preference
Payer Coverage of Biosimilars Varies by Preference
Payer Coverage of Biosimilars Varies by Preference
October 31, 2023
A poster from AMCP Nexus quantified tends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still varies.
CarePartners Adds Yuflyma to its Cost Savings Program
CarePartners Adds Yuflyma to its Cost Savings Program
CarePartners Adds Yuflyma to its Cost Savings Program
October 30, 2023
The Humira biosimilar Yuflyma will be available through CarePartners specialty pharmacy business, which has 10 million plan members.
J&J Warns of Risk of Respiratory Depression with Spravato
J&J Warns of Risk of Respiratory Depression with Spravato
J&J Warns of Risk of Respiratory Depression with Spravato
October 27, 2023
Based on reports from post-marketing experience, Spravato’s warnings and precautions section now includes the risk of respiratory depression.
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
October 27, 2023
The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
October 26, 2023
In new data, 60% of the patients with early stage Alzheimer’s disease and who have low levels of the protein tau achieved cognitive improvement when treated with Leqembi.
© 2024 MJH Life Sciences

All rights reserved.